BiotechTube

UCB0107 (bepranemab)

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Progressive Supranuclear Palsy

Conditions

Progressive Supranuclear Palsy

Trial Timeline

Nov 16, 2020 → Dec 13, 2027

NCT ID
NCT04658199

About UCB0107 (bepranemab)

UCB0107 (bepranemab) is a phase 1 stage product being developed by UCB for Progressive Supranuclear Palsy. The current trial status is active. This product is registered under clinical trial identifier NCT04658199. Target conditions include Progressive Supranuclear Palsy.

What happened to similar drugs?

2 of 20 similar drugs in Progressive Supranuclear Palsy were approved

Approved (2) Terminated (4) Active (14)
✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
✅Imatinib mesylateNovartisApproved
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3
🔄Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
❌FTY720 + PlaceboNovartisPhase 3
🔄BAF312 + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04658199Phase 1Active

Competing Products

20 competing products in Progressive Supranuclear Palsy

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
32
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3
47
ABBV-8E12 + Placebo solution for IV infusion on Day 15AbbViePhase 2
27
Placebo + ABBV-8E12AbbViePhase 2
27
ABBV-8E12AbbViePhase 1
29
AZD4635 + Durvalumab + CabazitaxelAstraZenecaPhase 2
35
antisense oligonucleotide + placeboNovartisPhase 1
29
Trametinib 2 mgNovartisPre-clinical
26
EverolimusNovartisPhase 2
35
sunitinib + everolimus + chemotherapies recommended in franceNovartisPre-clinical
26
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
FTY720 + PlaceboNovartisPhase 3
32
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43
MayzentNovartisPre-clinical
26
BAF312 + PlaceboNovartisPhase 3
40
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)NovartisPhase 1/2
39